USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 0.2 mg in 1 ml - contraindicated in people with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicat

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - codeine phosphate 10 mg in 5 ml

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - chlordiazepoxide hydrochloride/clidinium bromide is indicated to control the emotional and somatic factors in gastrointestinal disorders. chlordiazepoxide hydrochloride/clidinium bromide may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. chlordiazepoxide hydrochloride/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. the more severe withdrawal symptoms have

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals - .beta.-carotene (unii: 01yae03m7j) (.beta.-carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4 - .beta.-carotene 4000 [iu] - pretab prescription multivitamin tablets are used for the nutritional support of pregnant and lactating women. this product is contraindicated for persons with a known hypersensitivity to any of the ingredients and for persons with conditions for which any of the ingredients are contraindicated.

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals - .beta.-carotene (unii: 01yae03m7j) (.beta.-carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4 - .beta.-carotene 4000 [iu] - this product is contraindicated in patients with a known hypersensitivity to any of the components contained in this product. this product is contraindicated for individuals with conditions for which any of the ingredients are contraindicated.

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), biotin (unii: 6so6u10h04) (b - ascorbic acid 100 mg - this product is contraindicated in patients with a known hypersensitivity to any of its components.

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals, llc - phendimetrazine tartrate (unii: 6985ip0t80) (phendimetrazine - unii:ab2794w8kv) - phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (bmi) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. below is a chart of body mass index (bmi) based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters the usefulness of agents of this class (see clinical pharmacology ) should be measured against possible risk factors inherent in their use such as those described below. phendimetrazine tartrate is indicated for use as mo

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals, llc - phendimetrazine tartrate (unii: 6985ip0t80) (phendimetrazine - unii:ab2794w8kv) - phendimetrazine tartrate tablets are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. the limited usefulness of agents of this class (see clinical pharmacology ) should be measured against possible risk factors inherent in their use such as those described below. known hypersensitivity or idiosyncratic reactions to sympathomimetics. advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and severe hypertension, hyperthyroidism and glaucoma. highly nervous or agitated patients. patients with a history of drug abuse. patients taking other cns stimulants, including monoamine oxidase inhibitors. phendimetrazine tartrate tablets are defined by the drug enforcement administration as a schedule iii controlled substance. phendimetrazine tartrate is related chemically and pharmacologically to the amphetamines. amphetamines and related stimulant drugs have been extensively abused and the possibility of

USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals, llc - phendimetrazine tartrate (unii: 6985ip0t80) (phendimetrazine - unii:ab2794w8kv) - fendique er is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (bmi) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. below is a chart of body mass index (bmi) based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters the usefulness of agents of this class (see clinical pharmacology ) should be measured against possible risk factors inherent in their use such as those described below. phendimetrazine tartrate is indicated for use as monotherapy only. fendique er is defined b